This post discusses recent fines imposed on pharmaceutical companies for pay-for-delay agreements and examines their impact on market competition and drug pricing. It analyses regulatory measures and the ongoing debate over the balance between innovation and consumer interests.
Read more about Restricting ‘Pay-for-Delay’ Agreements